Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins

A combination preparation of 1:1 mixture of the immunotoxins HD37-dgA and RFB4-dgA with potential antineoplastic activity. Anti-CD19 IgG monoclonal antibody HD37 and anti-CD22 IgG monoclonal antibody RFB4 are attached individually to a deglycosylated ricin A chain (dgA) via N-succinimidyl-oxycarbonyl-alpha-methyl-alpha-(2-pyridyldithio) toluene (SMPT) linker. Deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins bind to CD19- and CD22-expressing tumor cells, specifically delivering cytotoxic ricin A chain to leukemia cells expressing these antigens. Ricin A chain is toxic to ribosomal activity and protein synthesis, and inhibits cell growth. CD19 and CD22 molecules are cell surface antigens present on the majority of B acute lymphoblastic leukemia (ALL) cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:IgG-HD37-dgA/IgG-RFB4-dgA immunotoxins
US brand name:Combotox
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search